Ibandronate sodium

• CAT Number: A001092
• CAS Number: 138926-19-9
• Molecular Formula: C9H22NO7P2 • Na [H2O]
• Molecular Weight: 359.21
• Purity: ≥95%
• Synonyms: BM-21.0955
• Target: Apoptosis
• Storage: store at -20℃
• IUPAC Name: sodium;hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate;hydrate
• InChI: InChI=1S/C9H23NO7P2.Na.H2O/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);;1H2/q;+1;/p-1
• InChIKey: VBDRTGFACFYFCT-UHFFFAOYSA-M
• SMILES: CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)[O-].O.[Na+]

Ibandronate sodium (Cat No.:A001092) is a bisphosphonate drug primarily used to treat osteoporosis and prevent bone fractures in patients with metastatic bone disease, particularly in breast cancer. It works by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing the risk of fractures. Ibandronate is typically administered either orally or as an intravenous infusion. It has been shown to improve bone strength and reduce pain in bone metastasis. Potential side effects include gastrointestinal issues and rare cases of osteonecrosis of the jaw.